MDxHealth S.A.
NASDAQ:MDXHMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $57.59M
- Beta
- 0.38
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.58
Volume 0.65M
Average 4.27M
MDXH Net Income
Bottom-line profit, the starting point for calculating cash from operations.
MDxHealth S.A.NASDAQ: MDXH
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income grows 85.9% year over year
Q2 FY2026 net income of $7.12M (cash outflow) rose 85.9% year over year. Over 3 fiscal years it compounded at -27.6% a year.
Context
- Net income amounted to 13.4% of revenue in FY2025, down 14.1 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$25.33M (+75.8%) for the fiscal year ending Dec 2026, a step up from the -41.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$7.12M— QoQ
- Last fiscal yearDec 2025
- -$14.41M-41.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +85.9% | — | — |
| 1 year | -41.7% | +75.8% | +117.5 pp |
| 3-year CAGR | -27.6% | -0.4% | +27.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (14.41M) USD
- Year-over-year change
- +41.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (14.41M) | +41.7% |
| FY2024 | 2024-12-31 | (24.72M) | +9.5% |
| FY2023 | 2023-12-31 | (27.33M) | +27.9% |
| FY2022 | 2022-12-31 | (37.9M) | -41.2% |
| FY2021 | 2021-12-31 | (26.84M) | — |
Net Income vs competitors
How MDXH compares with its peers on the latest reported figures
- MDXH's FY2025 net income of $14.41M is the 9th largest of the 11 companies compared; the peer median is $47.98M.
- Its year-over-year change of -41.7% is the 7th highest of 10, against a peer median of -11.9%.
- Net income amounts to 13.4% of revenue for MDXH, versus a peer median of 49.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $104.19M | +117.6% | +3.5% | 71.9% | |
ZURAZura Bio Limited | LTM Mar 2026 | $77.43M | +24.7% | +35.9% | — |
| LTM Mar 2026 | $69.66M | -46.5% | -9.3% | 832.6% | |
| LTM Mar 2026 | $54.44M | -11.9% | +3.5% | — | |
| LTM Jun 2026 | $51.88M | -50.1% | -9.2% | 6.8% | |
| LTM Mar 2026 | $44.08M | — | — | 81.8% | |
| LTM Mar 2026 | $21.68M | -14.5% | +5.8% | 69.5% | |
| LTM Mar 2026 | $20.17M | +30.0% | -25.1% | 29.5% | |
| FY2025 | $14.41M | -41.7% | -27.6% | 13.4% | |
| LTM Mar 2026 | $6.38M | -84.0% | -59.6% | 9.0% | |
| LTM Mar 2026 | $4.24M | +113.0% | — | 9.6% | |
| Peer median (excluding MDXH) | $47.98M | -11.9% | -2.9% | 49.5% | |
Competitors are the stored peer set for MDXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.84M) | (37.9M) | (27.33M) | (24.72M) | (14.41M) |
| Depreciation & Amortization | 3.04M | 4.91M | 6.86M | 8.04M | 9.21M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.22M | 867K | 665K | 1.73M | 2.21M |
| Change in Working Capital | 360K | (1.57M) | (2.12M) | (3.86M) | 939K |
| Accounts Receivables | (1.38M) | (5.12M) | (1.68M) | (3.23M) | 2.32M |
| Inventory | 413K | (416K) | (452K) | (1.09M) | (1.93M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 550K |
| Other Working Capital | 1.33M | 3.97M | 20K | 458K | 0 |
| Other Non-Cash Items | (325K) | (429K) | 421K | 286K | (8.37M) |
| Operating Cash Flow | (22.55M) | (34.12M) | (21.5M) | (18.53M) | (10.42M) |
| Capital Expenditures | (896K) | (4.16M) | (5.02M) | (2.16M) | (1.16M) |
| Acquisitions (Net) | 0 | (25M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 11K | (1.25M) | (1.18M) | (448K) | (18.9M) |
| Investing Cash Flow | (885K) | (29.04M) | (3.93M) | (1.64M) | (20.06M) |
| Debt Repayment | (1.06M) | 22.13M | (3.27M) | 11.59M | 21.6M |
| Common Stock Issued | 68.57M | 0 | 39.6M | 40.74M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.01M) | (1.41M) | (4.05M) | (7.73M) | (8.91M) |
| Financing Cash Flow | 66.5M | 20.72M | 32.28M | 44.6M | 12.7M |
| Effect of Forex Changes | (520K) | (555K) | 25K | (14K) | 16K |
| Net Change in Cash | 42.55M | (43M) | 6.88M | 24.42M | (17.77M) |
| Free Cash Flow | (23.44M) | (38.28M) | (26.52M) | (20.69M) | (11.57M) |
MDxHealth S.A.
NASDAQ:MDXH
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.